Shared and separate functions of polo-like kinases and aurora kinases in cancer
The DOI matches its Crossref record; 228 of the 228 references it cites were found in a registry or an index.
Abstract
Large numbers of inhibitors for polo-like kinases and aurora kinases are currently being evaluated as anticancer drugs. Interest in these drugs is fuelled by the idea that these kinases have unique functions in mitosis. Within the polo-like kinase family, the emphasis for targeted therapies has been on polo-like kinase 1 (PLK1), and in the aurora kinase family drugs have been developed to specifically target aurora kinase A (AURKA; also known as STK6) and/or aurora kinase B (AURKB; also known as STK12). Information on the selectivity of these compounds in vivo is limited, but it is likely that off-target effects within the same kinase families will affect efficacy and toxicity profiles. In addition, it is becoming clear that interplay between polo-like kinases and aurora kinases is much more extensive than initially anticipated, and that both kinase families are important factors in the response to classical chemotherapeutics that damage the genome or the mitotic spindle. In this Review we discuss the implications of these novel insights on the clinical applicability of polo-like kinase and aurora kinase inhibitors.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In addition, some kinases and phosphatases simultaneously hit the same kinesins to tune the balance between phosphorylation and dephosphorylation to modulate activity or spindle targeting [56, 57].”
From Regulatory mechanisms that control mitotic kinesins (2015) · cites this paper as [56]
Citations
Cites
Items 201–228 of 228
Dual Role of Topoisomerase II in Centromere Resolution and Aurora B Activity
Coelho, P. A., Queiroz-Machado, J., Carmo, A. M., Moutinho-Pereira, S., Maiato, H., & Sunkel, C. E. (2008) · PLoS Biology · doi:10.1371/journal.pbio.0060207 · Cited by 76
Constitutive Expression of Murine Sak-a Suppresses Cell Growth and Induces Multinucleation
Schuurmans, C. J., Binkert, C., & Dennis, J. W. (1996) · Molecular and Cellular Biology · doi:10.1128/mcb.16.9.4665 · Cited by 76 · cited 1×
“Overexpression of PLK3 or PLK4 can suppress proliferatio”
BackgroundAurora kinase inhibitors synergize with paclitaxel to induce apoptosis in ovarian cancer cells
Scharer, C. D., Laycock, N., Osunkoya, A. O., Logani, S., McDonald, J. F., Benigno, B. B., & Moreno, C. S. (2008) · Journal of Translational Medicine · doi:10.1186/1479-5876-6-79 · Cited by 74
Lens, S. M. A., Rodríguez, J. A., Vader, G., Span, S. W., Giaccone, G., & Medema, R. H. (2006) · Molecular Biology of the Cell · doi:10.1091/mbc.e05-08-0727 · Cited by 74
Self-citationArchambault, V., D’Avino, P. P., Deery, M. J., Lilley, K. S., & Glover, D. M. (2008) · Genes & Development · doi:10.1101/gad.486808 · Cited by 73 · cited 1×
“In addition, the PBD can also bind client proteins in a phospho-independent manne”
BackgroundOke, A., Pearce, D., Wilkinson, R. W., Crafter, C., Odedra, R., Cavenagh, J. D., Fitzgibbon, J., Lister, A. T., Joel, S., & Bonnet, D. A. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-3203 · Cited by 72
Reindl, W., Yuan, J., Krämer, A., Strebhardt, K., & Berg, T. (2009) · ChemBioChem · doi:10.1002/cbic.200900059 · Cited by 69
Requirement of hCenexin for Proper Mitotic Functions of Polo-Like Kinase 1 at the Centrosomes
Soung, N., Kang, Y. H., Kim, K., Kamijo, K., Yoon, H., Seong, Y., Kuo, Y.-L., Miki, T., Kim, S. R., Kuriyama, R., et al. (2006) · Molecular and Cellular Biology · doi:10.1128/mcb.00671-06 · Cited by 69 · cited 1×
“This interaction requires CDK1-dependent phosphorylation of cenexin 1 (Ref”
Kimura, M., Mori, T., Conroy, J. M., Nowak, N. J., Satomi, S., Tamai, K., & Nagase, H. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-2149 · Cited by 67 · cited 1×
“Interestingly, two coding single nucleotide polymorphisms (SNPs) in AURKA (91 T>A (encoding F31I) and 169G>A (encoding V57I)), which reduce aurora kinase A activity to 15% of normal are associated with an increased risk of developing oesophageal cance”
BackgroundAurora kinases A and B and familial breast cancer risk
Tchatchou, S., Wirtenberger, M., Hemminki, K., Sutter, C., Meindl, A., Wappenschmidt, B., Kiechle, M. B., Bugert, P., Schmutzler, R. K., Bartram, C. R., et al. (2006) · Cancer Letters · doi:10.1016/j.canlet.2006.05.002 · Cited by 64 · cited 1×
“Although high expression levels of aurora kinase B are associated with poor prognosis in glioblastoma, ovarian carcinoma and hepatocellular carcinoma ( Table 3 ), the evidence for genetic alteration of the AURKB locus is minima”
BackgroundAurora B Kinase-Dependent Recruitment of hZW10 and hROD to Tensionless Kinetochores
Famulski, J. K., & Chan, G. K. T. (2007) · Current Biology · doi:10.1016/j.cub.2007.11.037 · Cited by 63 · cited 1×
“The recruitment of BUB1 to kinetochores is sensitive to aurora kinase B inhibitio”
BackgroundZHANG, D.-F., Shimizu, T., Araki, N., Hirota, T., Yoshie, M., Ogawa, K., Nakagata, N., Takeya, M., & Saya, H. (2008) · Oncogene · doi:10.1038/onc.2008.76 · Cited by 62 · cited 1×
“However, both p53-proficient and p53-deficient mice that overexpress aurora kinase A in the mammary glands do not develop malignant tumour”
BackgroundOverexpression of Aurora B is associated with poor prognosis in epithelial ovarian cancer patients
Chen, Y. J., Chen, C., Twu, N.-F., Yen, M., Lai, C., Wu, H., Wang, P.-H., & Yuan, C.-C. (2009) · Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin · doi:10.1007/s00428-009-0838-3 · Cited by 61
Targeting Mitosis for Anti-Cancer Therapy
Sudakin, V., & Yen, T. J. (2007) · BioDrugs · doi:10.2165/00063030-200721040-00003 · Cited by 61 · cited 1×
“To resolve this, a new generation of anti-mitotic agents has been developed that target kinesins and kinases with a unique role in mitosis, such as, EG5 (also known as KIF11), polo-like kinase 1 (PLK1) and aurora kinase A (AURKA; also known as STK6”
BackgroundThe inhibition of Aurora A abrogates the mitotic delay induced by microtubule perturbing agents
Wysong, D. R., Chakravarty, A., Hoar, K., & Ecsedy, J. A. (2009) · Cell Cycle · doi:10.4161/cc.8.6.7897 · Cited by 60
Ang, X. L., Seeburg, D. P., Sheng, M., & Harper, J. W. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m802475200 · Cited by 60
Polo-box domains confer target specificity to the Polo-like kinase family
van de Weerdt, B. C. M., Littler, D. R., Klompmaker, R., Huseinovic, A., Fish, A., Anastassis Perrakis, A., & Medema, R. H. (2008) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2008.02.019 · Cited by 60
Self-citationVader, G., Maia, A. F., & Lens, S. M. (2008) · Cell Division · doi:10.1186/1747-1028-3-10 · Cited by 56
Self-citationKiyomitsu, T., Iwasaki, O., Obuse, C., & Yanagida, M. (2010) · The Journal of Cell Biology · doi:10.1083/jcb.200908096 · Cited by 55
Pouwels, J., Kukkonen, A. M., Lan, W., Daum, J. R., Gorbsky, G. J., Stukenberg, P. T., & Kallio, M. J. (2007) · Cell Cycle · doi:10.4161/cc.6.13.4442 · Cited by 53 · cited 1×
“melanogaster Shugoshin and human SGOL1 are direct substrates of aurora kinase B in vitro , and a shugoshin mutant that is poorly phosphorylated by aurora kinase B fails to properly localize to centromere”
BackgroundKitajima, S., Kudo, Y., Ogawa, I., Tatsuka, M., Kawai, H., Pagano, M., & Takata, T. (2007) · PLoS ONE · doi:10.1371/journal.pone.0000944 · Cited by 52
Plk1 depletion in nontransformed diploid cells activates the DNA-damage checkpoint
Lei, M., & Erikson, R. L. (2008) · Oncogene · doi:10.1038/onc.2008.36 · Cited by 44
Activation of Polo-like Kinase 3 by Hypoxic Stresses
Wang, L., Gao, J., Dai, W. H., & Lu, L. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m801326200 · Cited by 42 · cited 1×
“, and most data on PLK3 are consistent with a role in genotoxic, hypoxic and oxidative stress response”
BackgroundPolo-Like Kinase-1 Controls Aurora A Destruction by Activating APC/C-Cdh1
van Leuken, R. J., Clijsters, L., van Zon, W., Lim, D., Yao, X., Wolthuis, R. M. F., Yaffe, M. B., Medema, R. H., & van Vugt, M. A. T. M. (2009) · PLoS ONE · doi:10.1371/journal.pone.0005282 · Cited by 39 · cited 1×
“Importantly, PLK1 enhances CDH1-dependent APC/C activity to promote the destruction of aurora kinase”
BackgroundSelf-citationLi, C.-C., Chu, H.-Y., Yang, C.-W., Chou, C., & Tsai, T. (2009) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-08-0483 · Cited by 34
Nair, J. S., de Stanchina, E., & Schwartz, G. K. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-1826 · Cited by 33 · cited 1×
“Indeed, evidence suggests that the pretreatment of cells with aurora inhibitors enhances the cytotoxic effect of DNA-damaging agent”
BackgroundAstrin regulates Aurora-A localization
Du, J., Jablonski, S. A., Yen, T. J., & Hannon, G. J. (2008) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2008.03.072 · Cited by 23
Intron/Exon organization and polymorphisms of the PLK3/PRK gene in human lung carcinoma cell lines
Wiest, J. S., Clark, A. M., & Dai, W. H. (2001) · Genes Chromosomes and Cancer · doi:10.1002/gcc.1204 · Cited by 17 · cited 1×
“, but no mutations were found in the coding region of PLK3 (Ref”
Background
Cited by
A landscape of driver mutations in melanoma
Hodis, E., Watson, I. R., Kryukov, G. V., Arold, S. T., Imielinski, M., Theurillat, J.-P., Nickerson, E., Auclair, D., Li, L., Place, C., et al. (2012) · Cell · doi:10.1016/j.cell.2012.06.024 · Cited by 2,610
“PP6 negatively regulates levels of the melanoma oncogeneCCND1 during G1 phase of the cell cycle (Stefansson and Brautigan, 2007) and is the major T-loop phosphatase for the mitotic kinase, Aurora A (AurA), which is amplified in a number of human cancers (Lens et al., 2010; Zeng et al., 2010).”
BackgroundThe chromosomal passenger complex (CPC): from easy rider to the godfather of mitosis
Carmena, M., Wheelock, M., Funabiki, H., & Earnshaw, W. C. (2012) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm3474 · Cited by 905
Rath, O., & Kozielski, F. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3310 · Cited by 496
Targeting Mitosis in Cancer: Emerging Strategies
Dominguez-Brauer, C., Thu, K. L., Mason, J. M., Blaser, H., Bray, M. R., & Mak, T. W. (2015) · Molecular Cell · doi:10.1016/j.molcel.2015.11.006 · Cited by 495
“AURKA is amplified in cancers of the breast, ovary, lung, bladder, stomach, pancreas, head-and-neck, and colon, whereas AURKB is overexpressed in breast cancer, NSCLC, glioblastoma, and prostate cancer (Boss et al., 2009; Lens et al., 2010; Malumbres, 2011).”
BackgroundPLK1, A Potential Target for Cancer Therapy
Liu, Z., Sun, Q., & Wang, X. (2017) · Translational Oncology · doi:10.1016/j.tranon.2016.10.003 · Cited by 454
“Among them, PLK1 was the most investigated [2].”
Background
Metadata
- Authors
- Lens, S. M. A., Voest, E. E., & Medema, R. H.
- Affiliations
- University Medical Center Utrecht (NL)
- Corresponding author
- Lens, Susanne M. A.
- Medema, René H.
- Venue
- Nature Reviews Cancer
- Published
- 2010-11-24
- Volume
- 10
- Issue
- 12
- Pages
- 825-841
- ISSN
- 1474-175X (ISSN-L)
- 1474-1768
- OpenAlex
- W1994488152
- Cited by
- 597
- References
- 227
- Citations by year
- 2026: 17 · 2025: 25 · 2024: 10 · 2023: 28 · 2022: 24 · 2021: 29 · 2020: 42 · 2019: 37 · 2018: 27 · 2017: 33 · 2016: 36 · 2015: 56 · 2014: 59 · 2013: 64 · 2012: 65
- FWCI
- 4.93
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature reviews. Cancer (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Microtubule and mitosis dynamics
- Physical Sciences › Chemistry › Organic Chemistry › Heterocyclic Compound Synthesis and Bioactivity
- Health Sciences › Medicine › Oncology › Cancer Treatment and Pharmacology
- Keywords
- Polo-like kinase, Aurora kinases, PLK1, AURKA, Aurora B kinase, mitosis, kinase inhibitors, anticancer agents, off-target effects, chemosensitization, targeted therapy
- MeSH terms
- Polo-Like Kinase 1, Animals, Chromatids, Humans, Mitosis, Neoplasms, Proto-Oncogene Proteins, Protein Serine-Threonine Kinases, Kinetochores, Cell Cycle Proteins, Protein Kinase Inhibitors, Cytokinesis, Aurora Kinase A, Aurora Kinase B, Aurora Kinases
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.